MedTrace Logo

Expression of DMBT1 in Colorectal Cancer Patients

NCT02901600 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 145

Last updated 2016-09-15

No results posted yet for this study

Summary

Although colorectal cancer is a preventable and curable disease if early stage tumors are removed, it is still the fourth cause of cancer worldwide and the second leading cause of death in many industrialized countries. The 5-year survival is about 55% often due to a late detection. Then, the identification of sensitive and specific molecular markers is therefore a major challenge for early diagnosis and prognosis of this disease.

Preliminary work have reported variations in the expression of DMBT1 (deleted in malignant brain tumor 1), a glycoprotein co-secreted with mucins in the light of the glands, during several stages of colon carcinogenesis. The goal of this study is to study by mass spectrometry (MS), alterations in the repertoire of glycosylation of mucins from colorectal tumors of various stages, grades, and recurrence status.

Conditions

Interventions

OTHER

Detection of the expression of DMTB1 by immunohistochemistry

Sponsors & Collaborators

  • Lille Catholic University

    lead OTHER

Principal Investigators

  • Adriana Mihalache, MD, PhD · GHICL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2015-06-30
Completion
2015-11-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02901600 on ClinicalTrials.gov